Scholarlink

<p>Fontan-Associated Liver Disease (FALD) is a dramatically emerging problem even if not precisely defined in term of debated diagnosis and surveillance protocols. We analyze FALD prevalence, clinical impact and implications in a European cohort of patients. It’s a retrospective observational multicenter study including Fontan patients operated between 1990 and 2022. Anatomical, clinical, surgical and liver-related data were collected, defining FALD as a spectrum of time-related structural–functional liver modifications due to congestive hepatopathy (from mild liver fibrosis to liver cirrhosis and hepatocellular carcinoma) diagnosed through multiparametric evaluations. 14 centers routinely conducted liver assessment after Fontan completion. Out of 2141 patients, 343 (16%) were diagnosed with FALD (M/F = 198/145; median age 18&#xa0;years, IQR 15–26) with a median follow-up time of 14&#xa0;years (IQR 9–20) from Fontan surgery. Among these, there were 19 (5.5%) deaths, 5 (26.3%) of whom related to advanced liver disease/cancer. FALD showed no significant association with gender (<i>p</i> = 0.4, adjusted <i>p</i>-value = 0.5), dominant ventricular morphology (<i>p</i> = 0.060, adjusted <i>p</i>-value = 0.086) nor surgery type (<i>p</i> = 0.3, adjusted <i>p</i>-value = 0.4). Significant association emerged between FALD and fenestration absence (<i>p</i> &lt; 0.001, adjusted <i>p</i>-value &lt; 0.001), systemic ventricular (<i>p</i> &lt; 0.001, adjusted <i>p</i>-value &lt; 0.001) and atrio-ventricular valve (<i>p</i> &lt; 0.001) dysfunction, III-IV NYHA classes (<i>p</i> &lt; 0.001, adjusted <i>p</i>-value &lt; 0.001), tachyarrhythmias (<i>p</i> &lt; 0.001) and liver stiffness ≥ 22&#xa0;kPa on transient elastography (<i>p</i> &lt; 0.001, adjusted <i>p</i>-value &lt; 0.001). The analysis demonstrated no significant association between FALD and abnormal liver function tests (<i>p</i> = 0.2), heart transplantation (<i>p</i> = 0.6, adjusted <i>p</i>-value = 0.6), worse survival (<i>p</i> = 0.38). This study shows significant mortality related to FALD, which is also associated to clinical signs of failing Fontan circulation, stressing the pressing need of universally shared diagnostic criteria and surveillance protocols, to prevent and/or early-identify FALD and its more lethal complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fontan-Associated Liver Disease (FALD) in the EUROFontan Experience. An Insight into European Awareness

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月13日

查看全文
  • Anna Gozzi,
  • Luca Vedovelli,
  • Emma Bergonzoni,
  • Irene Cao,
  • Emanuela Angeli,
  • Rossana Zanoni,
  • Roberta Biffanti,
  • Gianfranco Butera,
  • Kostantinos Dimopoulos,
  • Alvaro Gonzalez Rocafort,
  • Mark G. Hazekamp,
  • Andrzej Kansky,
  • Marien Lenoir,
  • Thomas Martens,
  • Giovanni Meliota,
  • Bart Meyns,
  • Matej Nosal,
  • Carlo Pace Napoleone,
  • Friso M. Rijnberg,
  • Eva Sames Dolzer,
  • Giuseppe Scrascia,
  • Ugo Vairo,
  • Joeri Van Puyvelde,
  • Giovanni Di Salvo,
  • Claudia Montanaro,
  • Massimo A. Padalino

摘要

Fontan-Associated Liver Disease (FALD) is a dramatically emerging problem even if not precisely defined in term of debated diagnosis and surveillance protocols. We analyze FALD prevalence, clinical impact and implications in a European cohort of patients. It’s a retrospective observational multicenter study including Fontan patients operated between 1990 and 2022. Anatomical, clinical, surgical and liver-related data were collected, defining FALD as a spectrum of time-related structural–functional liver modifications due to congestive hepatopathy (from mild liver fibrosis to liver cirrhosis and hepatocellular carcinoma) diagnosed through multiparametric evaluations. 14 centers routinely conducted liver assessment after Fontan completion. Out of 2141 patients, 343 (16%) were diagnosed with FALD (M/F = 198/145; median age 18 years, IQR 15–26) with a median follow-up time of 14 years (IQR 9–20) from Fontan surgery. Among these, there were 19 (5.5%) deaths, 5 (26.3%) of whom related to advanced liver disease/cancer. FALD showed no significant association with gender (p = 0.4, adjusted p-value = 0.5), dominant ventricular morphology (p = 0.060, adjusted p-value = 0.086) nor surgery type (p = 0.3, adjusted p-value = 0.4). Significant association emerged between FALD and fenestration absence (p < 0.001, adjusted p-value < 0.001), systemic ventricular (p < 0.001, adjusted p-value < 0.001) and atrio-ventricular valve (p < 0.001) dysfunction, III-IV NYHA classes (p < 0.001, adjusted p-value < 0.001), tachyarrhythmias (p < 0.001) and liver stiffness ≥ 22 kPa on transient elastography (p < 0.001, adjusted p-value < 0.001). The analysis demonstrated no significant association between FALD and abnormal liver function tests (p = 0.2), heart transplantation (p = 0.6, adjusted p-value = 0.6), worse survival (p = 0.38). This study shows significant mortality related to FALD, which is also associated to clinical signs of failing Fontan circulation, stressing the pressing need of universally shared diagnostic criteria and surveillance protocols, to prevent and/or early-identify FALD and its more lethal complications.